Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 0.92
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of ATYR is 1.8 and suggests 90% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Data is available to registered users only
Buy
Sell